On Apr. 20, 2016, Sanford Burnham Prebys Medical Discovery Institute (SBP) and GlaxoSmithKline (GSK), a global pharmaceutical company, announced the creation of the SBP-GSK Center for Translational Neuroscience.

The new Center, located on the SBP campus in La Jolla, brought together experts from SBP and GSK to investigate factors that influence brain function and potentially reverse or slow down neurodegeneration, with the aim of identifying and validating new therapeutic targets.

Under the three year agreement, GSK provided funding to create and support a research laboratory. Staffed by SBP scientists, postdoctoral candidates and technicians working alongside neuroscientists from GSK, the Center was designed to bolster research dedicated to translational neuroscience.